p53-Regulated GML gene expression in non-small cell lung cancer: A promising relationship to cisplatin chemosensitivity

European Journal of Cancer

Volumn 36, Issue 4, 2000, Pages 489-495

  Higashiyama, M ^a   Miyoshi, Y ^b   Kodama, K ^a   Yokouchi, H ^a   Takami, K ^a   Nishijima, M ^b   Nakayama, T ^b   Kobayashi, H ^c   Minamigawa, K ^c   Nakamura, Y ^b,d  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b Division of Clinical Genetics   (Japan)

^c Nitta Gelatin Inc   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

CD DST; Chemosensitivity; Cisplatin; GML; NSCLC; p53

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN P53; VINDESINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034105934     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00261-0     Document Type: Article

References (41)

1. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:1992;523-526.
2. Shimamura A., Fisher D.E. p53 in life and death. Clin. Cancer Res. 2:1996;435-440.
3. El-Deiry W.S., Harper J.W., O'Connor P.M.et al. WAF/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
4. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p-53 mediated transactivation. Cell. 69:1992;1237-1245.
5. Kastan M.B., Zhan Q., El-Deiry W.S.et al. A mammalian cell cycle checkpoint pathway utilizating p53 and GADD45 is defective in ataxia-teleangioectasia. Cell. 71:1992;587-597.
6. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
7. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
8. Lowe S.W., Ruley H.E., Jacks T., Houseman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
9. Furuhata T., Tokino T., Urano T., Nakamura Y. Isolation of a novel GPI-anchored gene specifically regulated by p53; correlation between its expression and anti-cancer drug sensitivity. Oncogene. 13:1996;1965-1970.
10. Brakenhoff R.H., Gerretsen M., Knippels E.M.C.et al. The human E48 antigen, high homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-to-cell adhesion. J. Cell Biol. 129:1995;1677-1689.
11. Petranka J.G., Fleenor D.E., Sykes K., Kaufman R.E., Rosse W.F. Structure of the CD59-encoding gene. further evidence of a relationship to murine lymphocyte antigen Ly-6 protein Proc. Natl. Acad. Sci. USA. 89:1992;7876-7879.
12. Fleming T.J., O'hUigin C., Malek T.R. Characterization of two novel Ly-6 genes. protein sequence and potential structural similarity to alpha-Bungarotoxin and other neurotoxins J. Immunol. 150:1993;5379-5390.
13. Stefanova I., Horejsi V., Ansotegui I.L., Knapp W., Stockinger H. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science. 254:1991;1016-1019.
14. Kimura Y., Furuhata T., Urano T., Hirata K., Nakamura Y., Tikino T. Genomic structure and chromosomal localization of GML (GPI-anchored molecule-like protein), a gene induced by p53. Genomics. 41:1997;477-480.
15. Statistics and Information Department. Malignant neoplasm of trachea, bronchus and lung. In Age adjusted death rates from malignant neoplasms by site, each prefecture. Tokyo, Ministry of Health and Welfare of Japan, 1991, 1-8.
16. Chemotherapy in non-small cell lung cancer. a meta-analysis using update data on individual patients from 52 randomized clinical trials Br. Med. J. 311:1995;899-909.
17. Carney D.N. Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin. Oncol. 23(Suppl. 16):1996;71-75.
18. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
19. Higashiyama M., Kodama K., Yokouchi H.et al. Immunohistochemical p53 protein status in non-small cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J. Surg. Oncol. 68:1998;19-24.
20. Katsuragi K., Chiba W., Matsubara Y., Ikeda S., Ueta C., Kinoshita M. A sensitive and high-resolution method for the detection of mutations in the p53 gene using fluorescence-based PCR-SSCP. Biomed. Res. 16:1995;273-279.
21. Koezuka M., Kondo N., Kobayashi H.et al. Drug sensitivity test for primary culture of human cancer cells using collagen gel embedded culture and image analysis. Int. J. Oncol. 2:1993;953-959.
22. Tanigawa N., Kitaika A., Yamakawa M., Tanisaka K., Kobayashi H. In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis. Anticancer Res. 16:1996;1925-1930.
23. Kobayashi H., Tanisaka K., Doi O.et al. An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int. J. Oncol. 11:1997;449-455.
24. Kodama K., Doi O., Tatsuta M., Kuriyama K., Tateishi R. Development of postoperative intrathoracic chemothermotherapy for lung cancer with objective of improving local cure. Cancer. 64:1989;1422-1428.
25. Kimura Y., Furuhata T., Shiratsuchi T.et al. GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene. 15:1997;1369-1374.
26. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J. Natl. Cancer Inst. 85:1993;2018-2023.
27. Nishio M., Koshikawa T., Kuroishi T.et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancers. J. Clin. Oncol. 14:1996;497-502.
28. Kagawa K., Inoue T., Tokino T., Nakamura Y., Akiyama T. Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. Biochem. Biophys. Res. Commun. 241:1997;481-485.
29. Shaw G.L., Gazdar A.F., Phelps R.et al. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival. comparison of non-small cell lung cancer and small cell lung cancer J. Cell Biochem. 24(Suppl.):1996;173-185.
30. Cortazar P., Gazdar A.F., Woods E.et al. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin. Cancer Res. 3:1997;741-747.
31. Rusch V., Klimstra D., Venkatraman E.et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 55:1995;5038-5042.
32. Kawasaki M., Nakanishi Y., Kuwano K., Yatsunami J., Takayama K., Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin. Cancer Res. 3:1997;1195-1200.
33. Beer T.W., Rowlands D.C., Crocker J. Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours. Thorax. 51:1996;526-529.
34. Ota E., Abe Y., Oshika Y.et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br. J. Cancer. 72:1995;550-554.
35. Volm M., Mattern J. Increased expression of Bcl-2 in drug-resistant squamous cell lung carcinomas. Int. J. Oncol. 7:1995;1333-1338.
36. Bai F., Nakanishi Y., Kawasaki M.et al. Immunohistochemical expression of glutathione S-transferase can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer. 78:1996;416-421.
37. Francis P.A., Kris M.G., Rigas J., Grant S.C., Miller V.A. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer. 12(Suppl.):1995;163-172.
38. Bunn P.A. Jr. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin. Oncol. 23(Suppl. 16):1996;18-25.
39. Tishler R.B., Lamppu D., Park S., Price B.D. Microtubule-active drugs Taxol, Vinblastine, and Nocodazole increase the levels of transcriptionally active p53. Cancer Res. 55:1995;6021-6025.
40. Vasey P.A., Jones N.A., Jenkins S., Dive C., Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol. 50:1996;1536-1540.
41. Wahl A.F., Donaldson K.L., Fairchild C.et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Natl. Med. 2:1996;72-79.